Clinical trial
Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
NCT00314210 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00314210 |
|---|---|
| Title | Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients. |
| Official title | A Multi-Centre,Double-Blind,Randomised-Withdrawal,Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine SR as Monotherapy in the Maintenance Treatment of Patients With GAD Following an Open-Label Stabilisation Period |
| Acronym | PLATINUM |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anxiety Disorders |
| Intervention type | Drug |
| Interventions | Quetiapine SR |
| Enrollment | 575 |
| Start date | Mar 1, 2006 |
| Completion | Aug 1, 2007 |
| First posted | Apr 13, 2006 |
| Last update posted | Mar 25, 2009 |
| Countries | Australia, Canada, Finland, Germany, Hungary, Indonesia, Philippines, Russia, South Korea, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: